The researchers conducted a search of published literature and clinical trials registry to assess the effect of rosiglitazone on cardiovascular morbidity and mortality. Studies were included in the meta-analysis if they were more than 24 weeks in duration, the study protocol included a randomised control group and the researchers had access to outcome data on MI and death from cardiovascular causes.
The researchers identified 42 trials which met their criteria for inclusion.
Analysis of the trials led to the conclusion that rosiglitazone is associated with a significant 43 per cent increase in risk of MI and with an increase in the risk of death from cardiovascular causes.
GlaxoSmithKline, the manufacturers of rosiglitazone, said they stand by the drug, stating that the benefits of its use outweigh any treatment risks.
What do you think? Comment below or email us at firstname.lastname@example.org